Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathy
Authors:
- Ricardo A. GalliRGRicardo A. Galli
- Tamara C. BorsboomTBTamara C. Borsboom
- Charlotte GinesteCGCharlotte Gineste
- Lorenza BroccaLBLorenza Brocca
- Maira RossiMRMaira Rossi
- Darren T. HweeDHDarren T. Hwee
- Fady I. MalikFMFady I. Malik
- Roberto BottinelliRBRoberto Bottinelli
- Julien GondinJGJulien Gondin
- Maria-Antonietta PellegrinoMPMaria-Antonietta Pellegrino
- Josine M. de WinterJWJosine M. de Winter
- Coen A.C. OttenheijmCOCoen A.C. Ottenheijm
Open Access
- 20 February 2024
- journal article
- research article
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 156 (4)
Abstract
Nemaline myopathies are the most common form of congenital myopathies. Variants in ACTA1 (NEM3) comprise 15–25% of all nemaline myopathy cases. Patients harboring variants in ACTA1 present with a heterogeneous disease course characterized by stable or progressive muscle weakness and, in severe cases, respiratory failure and death. To date, no specific treatments are available. Since NEM3 is an actin-based thin filament disease, we tested the ability of tirasemtiv, a fast skeletal muscle troponin activator, to improve skeletal muscle function in a mouse model of NEM3, harboring the patient-based p.Asp286Gly variant in Acta1. Acute and long-term tirasemtiv treatment significantly increased muscle contractile capacity at submaximal stimulation frequencies in both fast-twitch extensor digitorum longus and gastrocnemius muscle, and intermediate-twitch diaphragm muscle in vitro and in vivo. Additionally, long-term tirasemtiv treatment in NEM3 mice resulted in a decreased respiratory rate with preserved minute volume, suggesting more efficient respiration. Altogether, our data support the therapeutic potential of fast skeletal muscle troponin activators in alleviating skeletal muscle weakness in a mouse model of NEM3 caused by the Acta1:p.Asp286Gly variant.Keywords
Funding Information
- Netherlands Organisation for Health Research and Development (91819613, 09150161910168)
This publication has 84 references indexed in Scilit:
- Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseasesNature Medicine, 2012
- Actin Nemaline Myopathy Mouse Reproduces Disease, Suggests Other Actin Disease Phenotypes and Provides Cautionary Note on Muscle Transgene ExpressionPLOS ONE, 2011
- Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with CoresThe American Journal of Human Genetics, 2010
- A myopathy-linked tropomyosin mutation severely alters thin filament conformational changes during activationProceedings of the National Academy of Sciences, 2010
- Altered myofilament function depresses force generation in patients with nebulin-based nemaline myopathy (NEM2)Journal of Structural Biology, 2010
- Mutations and polymorphisms of the skeletal muscle α-actin gene (ACTA1)Human Mutation, 2009
- Nemaline Myopathy with Minicores Caused by Mutation of the CFL2 Gene Encoding the Skeletal Muscle Actin–Binding Protein, Cofilin-2The American Journal of Human Genetics, 2007
- A Novel Nemaline Myopathy in the Amish Caused by a Mutation in Troponin T1The American Journal of Human Genetics, 2000
- A mutation in the α tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathyNature Genetics, 1995
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970